メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
東京理科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
鈴木 立紀
准教授
薬学部
,
薬学科
ウェブサイト
https://www.tus.ac.jp/ridai/doc/ji/RIJIA01Detail.php?act=nam&kin=ken&diu=6E76
h-index
1526
被引用数
23
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2000
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(46)
類似のプロファイル
(6)
フィンガープリント
Tatsunori Suzukiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Angiogenesis
100%
Receptor Signaling
66%
Vascular Endothelial Growth Factor
61%
Tumor Growth
59%
Tumor Angiogenesis
57%
Bone Marrow Cells
54%
Granulation Tissue
51%
Vascular Endothelial Growth Factor Receptor (VEGFR)
48%
MPGES-1
48%
C-X-C Chemokine Receptor Type 4 (CXCR4)
39%
Wild Mice
39%
Calcitonin Gene-related Peptide
37%
Prostaglandins
36%
Angiotensin II Type 1 Receptor (AT1R)
36%
Cyclooxygenase-2
34%
Tumor Metastasis
32%
Endothelial Cells
30%
Prostaglandin E2
29%
Knock-in Mouse Model
29%
Bone Marrow
28%
Ulcer
27%
Lymphangiogenesis
27%
Receptor Subtypes
26%
EP3 Receptor
25%
P-selectin
24%
Tumor Cells
24%
Mediated Interaction
24%
WNK4
24%
Prostaglandin E Receptor
24%
Wound Healing
24%
Gastric Ulcer Healing
24%
Platelets
24%
Thromboxane A2 Receptor
24%
Celecoxib
23%
Tumor
23%
Ulcer Healing
21%
E-type
20%
Cyclooxygenase-2 Inhibitors
19%
AT1a
18%
Stromal Tissue
17%
Wound-induced
17%
Healing
17%
Thromboxane A2 (TXA2)
16%
Clinical Research
16%
Stromal Cells
16%
Clinical Trials
16%
Vascular Endothelial Growth Factor Expression
15%
Neuronal Network
15%
Receptor Knockout
15%
Prostaglandin E
15%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
75%
Neoplasm
71%
Vasculotropin
61%
Tumor Growth
48%
Granulation Tissue
43%
Ulcer Healing
40%
Wild Type Mouse
37%
Prostaglandin E Synthase 1
37%
Calcitonin Gene Related Peptide
37%
Stomach Ulcer
36%
Knockout Mouse
33%
Synthetase
31%
Wound
30%
Ulcer
27%
Cyclooxygenase 2
26%
Wound Healing
25%
Thromboxane
24%
Angiotensin 1A Receptor
24%
Prostaglandin E Receptor 3
24%
P-Selectin
24%
Angiotensin II
20%
Vasculotropin Receptor 1
19%
Prostaglandin E2
19%
Celecoxib
18%
Prostaglandin
16%
Gamma Chemokine
15%
Inflammation
15%
Tumor Necrosis Factor
15%
Fibroblast Growth Factor 2
14%
Neutralizing Antibody
14%
Prostaglandin E
14%
Acetylsalicylic Acid
14%
Clinical Trial
13%
Non-Steroidal Anti-Inflammatory Drug
13%
Clinical Research
13%
Lewis Carcinoma
13%
Diseases
13%
Tissue Repair
12%
COX-2 Inhibitor
12%
Potassium Acetate
12%
Prostaglandin E Synthase
12%
Selectin (Glycoprotein)
12%
Arachidonate 5 Lipoxygenase
12%
Leukotriene B4
12%
Aldosterone
12%
Bone Cancer
12%
Toxic Injury
12%
Pseudohypoaldosteronism
12%
Claudin
12%
Gelatinase B
12%
Medicine and Dentistry
Angiogenesis
76%
Neoplasm
49%
Vasculotropin
47%
Receptor
43%
Lymphangiogenesis
36%
Tumor Progression
35%
Cyclooxygenase 2
30%
Upregulation
27%
Granulation Tissue
26%
Vasculotropin Receptor 1
24%
Prostaglandin E Synthase 1
24%
Metastatic Carcinoma
24%
Stomach Ulcer
24%
Ulcer Healing
24%
Prostaglandin E Receptor 3
24%
Prostaglandin E2
20%
Endothelial Cell
19%
Bone Marrow Cell
19%
Wound
18%
Celecoxib
17%
Prostaglandin
17%
Stromal Cell
16%
Stromal Tumor
16%
Ulcer
15%
Prostaglandin E
14%
Acetylsalicylic Acid
14%
Cyclooxygenase 2 Inhibitor
13%
Nonsteroid Antiinflammatory Agent
13%
Lung
13%
Lymph Flow
13%
Fibroblast Growth Factor 2
12%
Prostaglandin E Synthase
12%
Bone Cancer
12%
Stroma
12%
Tumor Cell
12%
Angiotensin 1A Receptor
12%
Cancer Growth
12%
PADGEM Protein
12%
Epidermal Growth Factor
12%
Gelatinase B
12%
Synthetase
12%
Chemokine Receptor
12%
Chemokine
12%
Platelet
12%
Gamma Chemokine
12%
Secondary Lymphedema
12%
Angiotensin 1 Receptor
12%
Oligodendrocyte
12%
Fibroblast
10%
Neutralizing Antibody
8%
